tert-butyl 5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-ylcarbamate

‌Upadacitinib Intermediate (CAS 1310726-60-3) | GMP-Certified API Precursor for JAK Inhibitor & Autoimmune Drug Synthesis‌

‌Overview‌

Upadacitinib Intermediate is a ‌pharmaceutical-grade chemical building block‌ critical for synthesizing ‌Upadacitinib (Rinvoq®)‌—a FDA-approved JAK1 inhibitor targeting ‌rheumatoid arthritis, psoriasis, and ulcerative colitis‌‌13. With ≥99% purity (validated by GC-MS/HPLC), it complies with ‌USP/EP standards‌ for API manufacturing and clinical trial material preparation‌14.

‌Key Applications‌

🔬 ‌Drug Development‌:

• Core precursor for 

  ‌JAK1 inhibitor optimization‌

  , enhancing therapeutic efficacy in autoimmune and inflammatory diseases‌34.

• Supports 

  ‌Rinvoq® generics R&D‌

   and novel drug formulations‌14.

🏭 ‌Industrial Use‌:

• Scalable synthesis under 

  ‌GMP guidelines‌

   for bulk API production‌45.

‌Product Specifications‌

✅ ‌Purity‌: ≥99% (COA provided; residual solvents <30 ppm)‌45.
⚪ ‌Form‌: White crystalline powder with solubility in DMSO and ethanol‌14.
📦 ‌Packaging‌: Custom options (1 kg to 50 kg) with nitrogen-sealed containers for stability‌45.
🌡️ ‌Storage‌: 24-month shelf life at -20°C in moisture-proof packaging‌15.

‌Quality Assurance‌

📄 ‌GMP Compliance‌: Manufactured in ISO-certified facilities with batch-specific traceability‌45.
🔍 ‌Analytical Support‌: Includes chiral purity, heavy metals (<5 ppm), and microbial limit testing‌46.

‌Supply Advantages‌

🌍 ‌Global Stock‌: Available in US, EU, and APAC warehouses for expedited shipping‌15.
🛠️ ‌Tailored Services‌: Technical documentation (EDMF, CMC) and regulatory support‌45.

‌Keywords‌: Upadacitinib Intermediate CAS 1310726-60-3, JAK Inhibitor Synthesis, Autoimmune Drug Development, GMP Pharmaceutical Intermediates, Rheumatoid Arthritis API Precursors‌13.